Anti-Human DLL4 Recombinant Antibody(Demcizumab)
-
产品编号
YR1276
-
别名
科研级 Demcizumab ( 登赛珠单抗 ), Anti-DLL4 Recombinant Antibody, Research Grade Demcizumab
-
规格
- 1mg
- 5mg
Alias | 科研级 Demcizumab ( 登赛珠单抗 ), Anti-DLL4 Recombinant Antibody, Research Grade Demcizumab |
Catalog Number | YR1276 |
Molecular Name | Demcizumab |
Host | Mouse |
Size | 1mg, 5mg |
Clonity | Monoclonal |
Purity | >95% as determined by SDS-PAGE |
Concentration | 1mg/ml |
Antibody Isotype | IgG2 Kappa |
Formulation | PBS, pH7.5 |
Background | Demcizumab /dɛmˈsɪzʊmæb/ is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene. |
CAS Number | 1243262-17-0 |
Application | ELISA, FCM, IP, FuncS, IF, Neut, WB |
Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Remarks | This product is for research use only. |
Shipping Condition | Shipped on ice packs. |
Target | DLL4[Homo sapiens] |